Figure 1: The survival curves of the pirfenidone add-on group and the control group.
(A) Survival analysis of all patients showed that the pirfenidone add-on group had fewer deaths than the control group, but the difference was not significant. (B) The pirfenidone add-on had no impact on the survival of patients with acute ILD (disease duration <3 months). (C) The pirfenidone add-on led to a significantly higher survival rate in subacute ILD patients (disease duration 3–6 months) compared with the control subgroup.
&
>>1013
すみません。風説でも何でもないですよ。
ttp://www.nature.com/articles/srep33226
GNIがプレスリリースで流用した論文の内容を記載しただけです。
風説でも何でもありません。
Figure 1: The survival curves of the pirfenidone add-on group and the control group.
(A) Survival analysis of all patients showed that the pirfenidone add-on group had fewer deaths than the control group, but the difference was not significant. (B) The pirfenidone add-on had no impact on the survival of patients with acute ILD (disease duration <3 months). (C) The pirfenidone add-on led to a significantly higher survival rate in subacute ILD patients (disease duration 3–6 months) compared with the control subgroup.